Adalimumab — CPB 0655 | AETNA Coverage Update

Aetna modified CPB 0655 covering adalimumab (Humira) and 11 biosimilar products, effective January 9, 2026. Here's what billing teams need to do.

Aetna updated its adalimumab coverage policy under CPB 0655 on January 9, 2026. This update covers Humira and 10 biosimilars — including Amjevita, Hadlima, Cyltezo, Yuflyma, Idacio, Hyrimoz, Abrilada, Yusimry, Hulio, and Simlandi — across commercial medical plans. The primary billing codes affected include J0139 (adalimumab, 1 mg) and biosimilar HCPCS codes Q5140 through Q5145. If your practice treats RA, Crohn's, psoriasis, or any of the other covered indications, this policy update changes what documentation you need before you bill.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Adalimumab — CPB 0655 | Aetna Coverage Update
Policy Code	CPB 0655
Change Type	Modified
Effective Date	January 9, 2026
Impact Level	High
Specialties Affected	Rheumatology, Dermatology, Gastroenterology, Ophthalmology, Oncology, Hematology
Key Action	Audit documentation for biomarker testing (CPT 86200, 86430, 86431, 86140) and step therapy before submitting prior auth requests

---

Aetna Adalimumab Coverage Criteria and Medical Necessity Requirements 2026

The real issue with this policy is the layered step-therapy logic. Aetna doesn't just ask whether the drug is appropriate — it asks whether you documented the right biomarkers, tried the right drugs first, and failed them in the right sequence. Miss one layer, and you're looking at a claim denial.

Aetna considers adalimumab or its biosimilar medically necessary only when specific criteria are met by indication. The prescriber specialty requirement alone will trip up practices that rely on general internists or PCPs: the prescription must come from — or be written in consultation with — a specialty-matched physician. Rheumatologists cover RA, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and Behcet's disease. Gastroenterologists must prescribe for Crohn's and ulcerative colitis. Dermatologists handle plaque psoriasis and pyoderma gangrenosum. Uveitis requires an ophthalmologist or rheumatologist.

Rheumatoid Arthritis Criteria

For RA, Aetna will approve adalimumab billing under two pathways. The first is straightforward: the member received a biologic or targeted synthetic drug (such as Rinvoq or Xeljanz) for moderately to severely active RA within the past 120 days. The second pathway is more demanding.

Under the second pathway, the member must have positive biomarker testing — either rheumatoid factor (RF, CPT 86430 or 86431) or anti-cyclic citrullinated peptide antibody (anti-CCP, CPT 86200) — or have been tested for all three: RF, anti-CCP, and CRP/ESR (CPT 86140, 86141, 85651, or 85652). Testing must be documented. If it isn't in the chart, it didn't happen as far as prior authorization is concerned.

Beyond biomarkers, the member must have failed a 3-month trial of methotrexate (MTX) at a maximum titrated dose of at least 15 mg per week, or been unable to tolerate it. Failure alone isn't enough — Aetna also requires documented inadequate response to MTX in combination with at least one other conventional synthetic drug (hydroxychloroquine and/or sulfasalazine), or a documented contraindication or intolerable adverse event to those agents. Moderate to high disease activity is one qualifying condition within the MTX failure pathway — it does not bypass the MTX trial requirement on its own.

This is a dense step-therapy requirement. If your RA patients are moving to adalimumab after MTX failure, your clinical documentation needs to show the specific drugs tried, the doses reached, the duration, and the response — or the prior auth will be denied.

Other Covered Indications

Aetna's coverage policy extends adalimumab coverage to a wide range of indications beyond RA. Each has its own step-therapy and prescriber requirements. The indications covered — when criteria are met — include:

Each indication has its own prior authorization path. Don't assume RA criteria carry over to psoriatic arthritis or Crohn's — they don't.

Tuberculosis Screening

Aetna requires TB screening before initiating adalimumab. Your documentation should include results from CPT 86480 or 86481 (TB gamma interferon tests) or CPT 86580 (intradermal TB skin test). Missing TB screening documentation is a fast path to a prior auth denial and delayed reimbursement.

---

Aetna Adalimumab Exclusions and Non-Covered Indications

Aetna does not consider adalimumab medically necessary for members who do not meet the step-therapy and prescriber requirements described above. The policy treats these cases as not meeting medical necessity — not as experimental designations — but the billing outcome is the same: denial.

The policy also covers situations where adalimumab is considered experimental or investigational for indications not listed in the approved criteria. If a clinician is using adalimumab off-label for an unlisted indication, Aetna will not cover it under this coverage policy without additional supporting evidence reviewed through a separate exception process.

---

Coverage Indications at a Glance

---

Aetna Adalimumab Billing Guidelines and Action Items 2026

This policy is now in effect as of January 9, 2026. If you haven't already audited your workflows against these criteria, do it now — not after your next denial.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Adalimumab Under CPB 0655

Primary HCPCS Codes for Adalimumab Billing

Supporting Diagnostic and Administration CPT Codes

The full CPB 0655 policy also lists CPT codes 96401–96450 (chemotherapy administration codes). Those codes are not reproduced here. Pull the complete code set from the CPB 0655 policy text if your practice bills chemotherapy administration in connection with adalimumab therapy.

Related Drug HCPCS Codes (Referenced in Policy for Step Therapy Documentation)

ICD-10-CM Diagnosis Codes

The policy lists 411 ICD-10-CM codes. The full code set covers the approved indications above — RA, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, juvenile idiopathic arthritis, hidradenitis suppurativa, uveitis, Behcet's disease, pyoderma gangrenosum, and immune checkpoint inhibitor-related toxicity. Use the CPB 0655 full policy text to pull the exact codes for your ICD-10 charge capture mapping. Billing adalimumab with an unsupported ICD-10 code is a direct path to a claim denial, even when clinical criteria are otherwise met.

---